Participated · Series C · May 2026

Toregem BioPharma is developing TRG-035, an experimental antibody therapy designed to neutralize USAG-1, a protein that suppresses tooth formation, with the goal of reactivating dormant tooth buds and prompting natural tooth development. The company’s initial clinical focus is on patients with congenital tooth agenesis, with broader potential envisioned for stimulating a “third dentition” to treat tooth loss from aging, decay, or injury. Preclinical evidence of tooth regeneration has come primarily from animal studies (mice), while human testing to date has focused on safety. Toregem launched a Phase I trial at Kyoto University Hospital in October 2024 that enrolled 30 healthy adult men missing at least one molar; recruitment was reported to have stopped by March 2026 and the study is operationally complete, though full results have not been published. Toregem has secured a mix of equity financing and non-dilutive support (grants and subsidies) and reports cumulative funding above $29 million. The company is using its recent Pre-Series C proceeds to advance Phase II trials in Japan and to prepare for clinical development in the United States.

Participated · Series A · Mar 2026

Founded in January 2024 and based in Tokyo, Orbital Lasers develops compact, high-efficiency lasers and space optical technologies intended for satellite lidar, space-debris removal, and related space systems. The company bases its R&D on joint research with RIKEN and is conducting concept design and mission hardware prototyping with JAXA for a small high-precision lidar satellite. It has also begun research with the Japanese Ministry of Defense on on-orbit ranging and surveillance technologies. To date the company completed a ¥9億円 seed round in December 2024 and has now raised a total of ¥39.2億円 in cumulative equity after this Series A. Orbital Lasers plans to integrate transmission, reception, and satellite-bus technologies to create differentiated system-level capabilities and pursue commercialization and global market deployment in the 2030s.

Participated · Series B · Feb 2026

Founded in 2023 and headquartered in Osaka, Japan, A-wave focuses on digital medical technologies for the growing population of chronic heart-failure patients. Its flagship product is an at-home monitoring system that applies cardiology specialist diagnostic know-how to continuously track patient condition and flag deterioration triggered by excess salt intake, overwork, or other stressors. The company aims to establish a medical framework that enables early intervention and thereby lowers rehospitalization rates. Proceeds from its latest funding will finance a nationwide clinical trial of the device in partnership with multiple Japanese medical institutions. Insights from the trial will be used to refine the system and prepare it for practical commercialization. A-wave also plans to deepen collaborations with relevant academic societies and healthcare providers to build a robust deployment ecosystem. No revenue or user metrics have been disclosed to date.

Participated · Series B · Oct 2025

Celaid Therapeutics is a university-spin-out leveraging proprietary technology to selectively expand human hematopoietic stem cells (HSCs) for therapeutic use. Its lead candidate, CLD-001, targets severe pediatric non-malignant blood disorders by using cord-blood–derived HSCs that are expanded to overcome donor-shortage and HLA-mismatch limitations. Recent pre-clinical studies have shown positive efficacy and safety data, while chemistry, manufacturing and controls (CMC) work and FDA pre-IND preparation are underway. Beyond its own pipeline, Celaid licenses its HSC expansion platform to pharmaceutical and biotech partners and is collaborating with AGC Inc. on iPSC-derived HSPCs. The company plans to use fresh capital to fund GMP manufacturing, U.S. IND-enabling studies, and platform expansion into broader cell and gene therapy programs. Including grants and subsidies, Celaid has raised a cumulative JPY 2.52 billion (USD 17.14 million) to date.

Participated · Series A · Aug 2025

3DC develops and manufactures Graphene MesoSponge® (GMS), a three-dimensional graphene material with porosity, conductivity, flexibility, and corrosion resistance intended to address trade-offs in battery performance. The company was founded in February 2022 and is headquartered at Tohoku University in Sendai, with a Kawasaki office and a pilot factory in Toki, Gifu where construction of the world’s first GMS mass-production facility has begun. Following a Series A 1st-close in August 2025 and ongoing validation work, 3DC is supplying functional conductive additive GMS to numerous domestic and international battery makers for evaluation. 3DC plans to use recent and prior funding to expand its pilot factory into a mass-production plant, establish ton-scale production processes, strengthen global supply for customer evaluations and commercialization, and expand R&D talent and overseas partnerships. The company positions partnerships with established industry players and strategic investors as key to accelerating production, supply-chain stabilization, and market adoption of GMS.